

UNITED STATES BANKRUPTCY COURT

DISTRICT OF Delaware

In re: Insys Therapeutics, Inc., et al.

§
§
§
§

Case No. 19-11292

Lead Case No. 19-11292

Debtor(s)

☒ Jointly Administered

Post-confirmation Report

Chapter 11

Quarter Ending Date: 12/31/2025

Petition Date: 06/10/2019

Plan Confirmed Date: 01/16/2020

Plan Effective Date: 02/18/2020

This Post-confirmation Report relates to: ☐ Reorganized Debtor

☒ Other Authorized Party or Entity: Insys Liquidation Trust

Name of Authorized Party or
Entity

/s/ Alan D. Halperin

Signature of Responsible Party

01/15/2026

Date

Alan D. Halperin

Printed Name of Responsible Party

Halperin Battaglia Benzija, LLP
40 Wall Street, 37th Floor
New York, NY 10005
Address

STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, Paperwork Reduction Act exemption 5 C.F.R. § 1320.4(a)(2) applies.

Debtor's Name Insys Therapeutics, Inc., et al.

Case No. 19-11292

Part 1: Summary of Post-confirmation Transfers

	Current Quarter	Total Since Effective Date
a. Total cash disbursements	\$606,383	\$29,618,596
b. Non-cash securities transferred	\$0	\$0
c. Other non-cash property transferred	\$0	\$0
d. Total transferred (a+b+c)	\$606,383	\$29,618,596

Part 2: Preconfirmation Professional Fees and Expenses

a.			Approved Current	Approved Cumulative	Paid Current Quarter	Paid Cumulative
	Professional fees & expenses (bankruptcy) incurred by or on behalf of the debtor	Aggregate Total	\$0	\$0	\$0	\$10,199,965
	Itemized Breakdown by Firm					
	Firm Name	Role				
i	ALTO Litigation	Special Counsel	\$0	\$0	\$0	\$2,838
ii	Andersen Tax	Financial Professional	\$0	\$0	\$0	\$60,664
iii	Carlton Fields	Other	\$0	\$0	\$0	\$435,811
iv	Columbus	Other	\$0	\$0	\$0	\$3,900
v	Dinsmore & Shohi	Special Counsel	\$0	\$0	\$0	\$4,538
vi	DLA Piper	Special Counsel	\$0	\$0	\$0	\$3,942
vii	Ernst & Young	Financial Professional	\$0	\$0	\$0	\$5,200
viii	Epiq	Other	\$0	\$0	\$0	\$1,124,069
ix	FTI Consulting	Financial Professional	\$0	\$0	\$0	\$3,891,025
x	Gibbons	Special Counsel	\$0	\$0	\$0	\$8,525
xi	Hampton Barghois Pierce	Special Counsel	\$0	\$0	\$0	\$3,483
xii	Holland & Knight	Special Counsel	\$0	\$0	\$0	\$120,436
xiii	Lazard Freres	Financial Professional	\$0	\$0	\$0	\$1,478,864
xiv	Miller Friel	Special Counsel	\$0	\$0	\$0	\$69,684
xv	Rakoczy Molion Mazzochi	Special Counsel	\$0	\$0	\$0	\$5,917
xvi	Resolutions Inc.	Special Counsel	\$0	\$0	\$0	\$25,000
xvii	Richards Layton & Finger	Special Counsel	\$0	\$0	\$0	\$1,018,507
xviii	Rose Law Firm	Special Counsel	\$0	\$0	\$0	\$3,617
xix	Shook Hardy & Bacon	Special Counsel	\$0	\$0	\$0	\$543
xx	Spiro Harrison	Special Counsel	\$0	\$0	\$0	\$45,839
xxi	Squire Patton Boggs	Special Counsel	\$0	\$0	\$0	\$354
xxii	Weil Gotshal & Manges	Lead Counsel	\$0	\$0	\$0	\$1,759,519
xxiii	Wilson Sonsini Goodrich & Ros	Special Counsel	\$0	\$0	\$0	\$127,690
xxiv						
xxv						
xxvi						
xxvii						
xxviii						
xxix						

Debtor's Name Insys Therapeutics, Inc., et al.

Case No. 19-11292

xxx						
xxxi						
xxxii						
xxxiii						
xxxiv						
xxxv						
xxxvi						
xxxvii						
xxxviii						
xxxix						
xl						
xli						
xlii						
xliii						
xliv						
xlv						
xlvi						
xlvii						
xlviii						
xlix						
l						
li						
lii						
liii						
liv						
lv						
lvi						
lvii						
lviii						
lix						
lx						
lxi						
lxii						
lxiii						
lxiv						
lxv						
lxvi						
lxvii						
lxviii						
lxix						
lxx						
lxxi						

b.				Approved Current	Approved Cumulative	Paid Current Quarter	Paid Cumulative
	Professional fees & expenses (nonbankruptcy) incurred by or on behalf of the debtor <i>Aggregate Total</i>						
	<i>Itemized Breakdown by Firm</i>						
		Firm Name	Role				
	i						
	ii						
	iii						
	iv						
	v						
	vi						

Debtor's Name Insys Therapeutics, Inc., et al.

Case No. 19-11292

	vii					
	viii					
	ix					
	x					
	xi					
	xii					
	xiii					
	xiv					
	xv					
	xvi					
	xvii					
	xviii					
	xix					
	xx					
	xxi					
	xxii					
	xxiii					
	xxiv					
	xxv					
	xxvi					
	xxvii					
	xxviii					
	xxix					
	xxx					
	xxxi					
	xxxii					
	xxxiii					
	xxxiv					
	xxxv					
	xxxvi					
	xxxvii					
	xxxviii					
	xxxix					
	xl					
	xli					
	xlii					
	xliii					
	xliv					
	xlv					
	xlvi					
	xlvii					
	xlviii					

Debtor's Name Insys Therapeutics, Inc., et al.

Case No. 19-11292

	xlix					
	l					
	li					
	lii					
	liii					
	liv					
	lv					
	lvi					
	lvii					
	lviii					
	lix					
	lx					
	lxi					
	lxii					
	lxiii					
	lxiv					
	lxv					
	lxvi					
	lxvii					
	lxviii					
	lxix					
	lxx					
	lxxi					
	lxxii					
	lxxiii					
	lxxiv					
	lxxv					
	lxxvi					
	lxxvii					
	lxxviii					
	lxxix					
	lxxx					
	lxxxi					
	lxxxii					
	lxxxiii					
	lxxxiv					
	lxxxv					
	lxxxvi					
	lxxxvii					
	lxxxviii					
	lxxxix					
	xc					

Debtor's Name Insys Therapeutics, Inc., et al.

Case No. 19-11292

	xcv						
	xcvi						
	xcvii						
	xcviii						
	xcix						
	c						
	ci						
c.	All professional fees and expenses (debtor & committees)					\$0	\$11,876,616

Part 3: Recoveries of the Holders of Claims and Interests under Confirmed Plan

	Total Anticipated Payments Under Plan	Paid Current Quarter	Paid Cumulative	Allowed Claims	% Paid of Allowed Claims
a. Administrative claims	\$0	\$0	\$705,413	\$705,413	100%
b. Secured claims	\$0	\$0	\$0	\$0	0%
c. Priority claims	\$0	\$0	\$165,597	\$165,597	100%
d. General unsecured claims	\$0	\$0	\$0	\$0	0%
e. Equity interests	\$0	\$0	\$0		

Part 4: Questionnairea. Is this a final report? Yes ☐ No ☒

If yes, give date Final Decree was entered: _____

If no, give date when the application for Final Decree is anticipated: _____

b. Are you current with quarterly U.S. Trustee fees as set forth under 28 U.S.C. § 1930? Yes ☒ No ☐

Debtor's Name Insys Therapeutics, Inc., et al.

Case No. 19-11292

Privacy Act Statement

28 U.S.C. § 589b authorizes the collection of this information and provision of this information is mandatory. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6) and to otherwise evaluate whether a reorganized chapter 11 debtor is performing as anticipated under a confirmed plan. Disclosure of this information may be to a bankruptcy trustee when the information is needed to perform the trustee's duties, or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee's systems of records notice, UST-001, "Bankruptcy Case Files and Associated Records." See 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http://www.justice.gov/ust/eo/rules_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case, or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F).

I declare under penalty of perjury that the foregoing Post-confirmation Report and its attachments, if any, are true and correct and that I have been authorized to sign this report.

/s/ William H. Henrich

Signature of Responsible Party

Liquidating Trustee of the Insys Liquidation Trust

Title

William H. Henrich


Printed Name of Responsible Party

01/15/2026


Date

Debtor's Name Insys Therapeutics, Inc., et al.


Case No. 19-11292



Page 1



Other Page 1




Page 2 Minus Tables


Bankruptcy Table 1-50

Debtor's Name Insys Therapeutics, Inc., et al.


Case No. 19-11292




Bankruptcy Table 51-100



Non-Bankruptcy Table 1-50



Non-Bankruptcy Table 51-100



Part 3, Part 4, Last Page